Sign in

AMIX on Nasdaq

Autonomix Medical, Inc.

In its 2026 annual report the company says: “We are a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Our platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency ablation, enabling a “sense, treat, verify” approach intended to improve the precision and consistency of nerve-targeted therapies.”4 It is headquartered in The Woodlands, Texas.1 Its shares trade on Nasdaq under the symbol AMIX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$0Revenue, fiscal 20262
-$16.7MNet income, fiscal 20262

Compare with another stock.

  • TickerAMIX on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersThe Woodlands, Texas1
  • Incorporated inDE3
  • Business address21 Waterway Avenue, Suite 300, The Woodlands, Tx 773803
  • Filer category, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Our platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (“RF”) ablation, enabling a “sense, treat, verify” approach intended to improve the precision and consistency of nerve-targeted therapies.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-283.5%Return on equity2
-$12.3MFree cash flow2

Financial statements

Revenue562$0 in 2026
02023: $0$020232024: $0$020242025: $0$020252026: $0$02026
Operating income562-$17.0M in 2026+756% since 2023
-$20.0M-$15.0M-$10.0M-$5.0M02023: -$2.0M-$2.0M20232024: -$12.0M-$12.0M2024+505%2025: -$11.6M-$11.6M2025−4%2026: -$17.0M-$17.0M2026+47%
Net income562-$16.7M in 2026+740% since 2023
-$20.0M-$15.0M-$10.0M-$5.0M02023: -$2.0M-$2.0M20232024: -$15.4M-$15.4M2024+675%2025: -$11.4M-$11.4M2025−26%2026: -$16.7M-$16.7M2026+46%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2026-03-312025-03-31
Research and development$7.1M$4.7M
General and administrative$9.9M$6.9M
Total operating expenses$17.0M$11.6M
Loss from operations-$17.0M-$11.6M
Interest expense$0-$176.0K
Interest income$319.0K$354.0K
Total other income, net$319.0K$178.0K
Loss before income taxes-$16.7M-$11.4M
Income taxes$0$0
Net loss-$16.7M-$11.4M
Loss per share - basic and diluted (in dollars per share)-$2.32-$6.46
Weighted average shares outstanding - basic and diluted (in shares)7.2M shares1.8M shares

Compare Autonomix Medical, Inc. with another company

Corporate structure

Autonomix Medical, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Autonomix Medical, Inc.

  • BioStar Ventures III, L.P. Filed SCHEDULE 13G/A on Autonomix Medical, Inc., latest Aug 14, 2025 (2 filings since Oct 7, 2024)
  • Cavalry Fund I LP Filed SCHEDULE 13G/A on Autonomix Medical, Inc., latest Aug 14, 2025 (2 filings since Dec 3, 2024)
  • CVI Investments, Inc. Filed SCHEDULE 13G/A on Autonomix Medical, Inc., latest Feb 7, 2025 (2 filings since Nov 27, 2024)
  • Landy Toth Filed SC 13D on Autonomix Medical, Inc., latest Feb 26, 2024
  • Walter Klemp V. Filed SC 13D on Autonomix Medical, Inc., latest Feb 15, 2024
  • Autonomix Medical, Inc. The Woodlands, Texas

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Autonomix Medical, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$19.0K2 Mar 31, 2026$21.0K2 Mar 31, 2025−9.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.0M2 Mar 31, 2026$9.1M2 Mar 31, 2025−23.3%

Properties, in its own words

We do not own any real property. Our corporate and executive offices are located in a facility in The Woodlands, Texas for which we are under a membership agreement. The current membership agreement terminates on November 30, 2026. We believe that our facilities are sufficient to meet our current needs and that suitable space will be available as and when needed.

Item 2 of the 10-K filed May 27, 2026.4

Leadership

Who has led Autonomix Medical, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lori Bisson2024
  2. Bradley Hauser2024–now

President

  1. Bradley Hauser2024–now

Chief financial officer

  1. Trent N. Smith2024–now
2025
Board members and other officers (5)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerMatthew Lourie named Mar 20, 2023 to Jun 1, 202317
  • Executive OfficerRobert Schwartz named Apr 6, 2022 to Jun 1, 202317
  • Executive OfficerMatt Lourie named Apr 6, 202218

Timeline

  1. Sep 16, 20268-K Executive or director change19
  2. Aug 26, 20268-K Entered a material agreement; Unregistered sale of shares; Other events20
  3. Jul 28, 20268-K Other events21
  4. Jul 15, 20268-K Entered a material agreement; Unregistered sale of shares; Other events22
  5. Jul 10, 20268-K Other events23
  6. Jun 24, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events24
  7. Jan 16, 20268-K Listing notice or transfer25
  8. Jan 9, 20268-K Regulation FD disclosure26
  9. Nov 19, 20258-K Entered a material agreement; Unregistered sale of shares27
  10. Nov 3, 20258-K Shareholder vote28
  11. Aug 27, 20258-K Other events29
  12. Aug 26, 20258-K Entered a material agreement; Unregistered sale of shares30
  13. Jun 20, 2024New chief executive Bradley Hauser becomes CEO11
  14. Jan 26, 2024New chief executive Lori Bisson becomes CEO10

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($28.99) a share, on Nov 12, 2025.31

When it reported results

  1. Feb 13, 2025Reported quarterly or annual results32
  2. Nov 12, 2024Reported quarterly or annual results33
  3. Aug 13, 2024Reported quarterly or annual results34
  4. May 31, 2024Reported quarterly or annual results35

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

147 filings to the SEC since October 2021: 6 annual reports, 8 quarterly reports, 31 major events, 24 insider forms, 8 large holders, 3 private raises, 67 other. The latest 20:

  1. Oct 13, 20263 EDGAR
  2. Sep 21, 20264 FORM 4 - SMITH, TRENT EDGAR
  3. Sep 16, 2026424B3 EDGAR
  4. Sep 16, 20268-K EDGAR
  5. Sep 15, 2026EFFECT EDGAR
  6. Sep 14, 2026DEFA14A EDGAR
  7. Sep 14, 2026DEF 14A EDGAR
  8. Sep 11, 2026424B5 EDGAR
  9. Sep 8, 20264 FORM 4 - KLEMP, WALLY EDGAR
  10. Sep 8, 20264 FORM 4 - BISSON, LORI EDGAR
  11. Sep 8, 20264 FORM 4 - HAUSER, BRAD EDGAR
  12. Sep 4, 2026PRE 14A EDGAR
  13. Sep 4, 2026S-3 EDGAR
  14. Aug 26, 20268-K EDGAR
  15. Aug 13, 202610-Q EDGAR
  16. Aug 4, 2026EFFECT EDGAR
  17. Jul 31, 2026424B5 EDGAR
  18. Jul 28, 2026S-3 EDGAR
  19. Jul 28, 20268-K EDGAR
  20. Jul 15, 20268-K EDGAR

The 147 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Brad Hauser - Chief Executive Officer and President$468.0K$670.2K41
2026Trent Smith - Chief Financial Officer$296.4K$381.8K41
2026Lori Bisson - Executive Vice Chairman$150.0K$204.0K41
2025Brad Hauser - Chief Executive Officer and President$356.2K$1.7M41
2025Lori Bisson - Executive Vice Chairman$210.0K$659.1K41
2025Trent Smith - Chief Financial Officer$295.0K$618.1K41

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$5.1M 2022–2023
Money received by yearMoney received by year, 2022–2023: $5.1M in all. Private raises (Form D) $5.1M.$0$1M$2M$3M$4M2022 · Private raises (Form D): $2.0M20222023 · Private raises (Form D): $3.1M2023
Figures by year
YearPrivate raises (Form D)Total
2023$3.1M$3.1M
2022$2.0M$2.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. May 17, 2023Raised $2.4 million in a private offering of equity17 Form D: $4 million offered in all Form D
  2. Mar 6, 2023Raised $675,000 in a private offering of equity42 Form D: 5 investors so far Form D
  3. Mar 25, 2022Raised $2 million in a private offering of equity18 Form D: 33 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Mariner, LLC50,138$25.6K0.0%New
Allied Private Wealth LLC347$2.2K0.0%New
Tower Research Capital LLC (TRC)313$1.9K0.0%New
PNC Financial Services Group, Inc.75$4670.0%New
Investors Research Corp8$500.0%New
Networth Advisors, LLC1$60.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Autonomix Medical, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAutonomix Medical, Inc.1
  • CIK0001617867
  • Employer ID (EIN)47-16078104
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsMarch 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address21 Waterway Avenue, Suite 300, The Woodlands, TX 773801
  • Phone832-277-78161
  • Shares outstanding971,043 as of Aug 6, 20269
  • Public float$6.3M as of Sep 30, 20254
  • AuditorForvis Mazars, LLP, Atlanta, Georgia PCAOB ID 686; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceSep 3, 20141
  • Filings148 in all: 8-K (31), 4 (15), 3 (9), 10-Q (8), CORRESP (8), EFFECT (8), UPLOAD (6), 424B3 (5)1
    All 34 form types

    D (4), S-3 (4), 1-A/A (3), 10-K (3), 10-K/A (3), 253G2 (3), 424B5 (3), DEF 14A (3), DEFA14A (3), PRE 14A (3), S-1 (3), SC 13G (3), SCHEDULE 13G/A (3), QUALIF (2), S-1/A (2), S-8 (2), SC 13D (2), 1-A (1), 1-A POS (1), 1-SA (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), POS AM (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) May 27, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Sep 14, 2026
    Latest 8-K (8-K) Sep 16, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.001 par valueAMIXNasdaq

From the cover page of the 10-K filed May 27, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Autonomix Medical, Inc. names in Item 1A of its 10-K filed May 27, 2026: 49 risks under these headings, as written.4

  • Risks Related to Our Overall Business
  • Risks Related to Government Regulation and Product Approvals
  • Risks Related to Intellectual Property
  • Risks Related to Information Technology
  • Risks Related to our Common Stock
  • Factors raise substantial doubt about our ability to continue as a going concern.
  • We have no approved products, and we cannot assure you that we will generate revenue or become profitable in the future.
  • We will need additional financing over the longer term to execute our business plan and fund operations, which additional financing may not be available on reasonable terms or at all.
  • We intend to utilize a single manufacturer for the manufacture of our lead product candidate and expect to continue to do so for commercial products. Risks associated with the manufacturing of our products could reduce our gross margins and negatively affect our operating results.
  • We are a developmental stage company and have not yet had a history of generating revenue.
  • Our business may be adversely affected by the state of the global economy, uncertainties in global financial markets, and possible trade tariffs and trade restrictions.
  • We have limited experience in assembling and testing our products and may encounter problems or delays in the assembly of our products or fail to meet certain regulatory requirements which could result in an adverse effect on our business and financial results.
The other 42 risks
  • Rapidly changing technology in life sciences could make the products we are developing obsolete.
  • Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
  • Catastrophic events and disaster recovery may disrupt business continuity.
  • We may fail to meet the Sarbanes-Oxley regulations and may lack the financial controls and safeguards required of public companies.
  • While our Company’s management is working to improve our internal controls and procedures, at present management has determined that our internal controls were deemed to be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.
  • Because of the specialized nature of our business, the termination of relationships with our key employees, consultants and advisors may prevent us from successfully operating our business, including developing our products, conducting clinical studies, commercializing our products and obtaining any necessary financing.
  • Changes to United States federal and state regulatory agencies may cause disruptions and delays in approval of the government approval processes and regulation relating to our products.
  • There is no guarantee that the FDA will grant 510(k) or de novo clearance or a premarket approval application (“PMA”) of our future products and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business.
  • Our product development for our sensing and ablation technologies may not meet the necessary validation requirements to achieve regulatory approvals, or our internal specifications for commercial viability.
  • Modifications to our future products may require new regulatory clearances or approvals or may require us to recall or cease marketing our products until clearances or approvals are obtained.
  • The results of our future clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.
  • We are conducting our initial Proof of Concept trial outside the United States using commercially available RF ablation equipment in a new anatomical region to assess clinical response. We plan to present the relevant data from this trial to the FDA to support the clinical requirements for clearance in the United States. However, there is no assurance that the FDA will accept this data.
  • Our clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.
  • We may have limitations in generating statistically significant long-term clinical data and gaining extended-duration indications from clinical studies involving terminal patients.
  • Even if our products are cleared or approved by the FDA, if we or our suppliers fail to comply with ongoing FDA requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal from the market.
  • Our products may in the future be subject to product recalls that could harm our reputation, business and financial results.
  • If our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.
  • Certain parts used in the manufacturing of our equipment may experience shortages in global supply, which could impact our ability to manufacture our device for customers or maintain research and development timelines.
  • U.S. legislative or FDA regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.
  • Failure to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products, if approved, and reduce our revenues.
  • We may not be successful in securing and maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or physician services attendant to our products.
  • If we are unable to establish good relationships with physicians, our business could be negatively affected.
  • There is no assurance that Medicare or the Medicare Administrative Contractors will provide coverage or adequate payment rates for our products.
  • If third parties claim that our products infringe their intellectual property rights, we may be forced to expend significant financial resources and management time defending against such actions and our financial condition and our results of operations could suffer.
  • If we are unable to protect the intellectual property used in our products, others may be able to copy our innovations which may impair our ability to compete effectively in our markets.
  • We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Our business and operations would suffer in the event of third-party computer system failures, cyberattacks on third-party systems or deficiency in our cybersecurity.
  • Artificial intelligence presents risks and challenges that can impact our business, including by posing security risks to our confidential information, proprietary information and personal data.
  • Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations.
  • We are not in compliance with Nasdaq’s continued listing requirements and if we are unable to regain compliance with the listing requirements, our common stock will be delisted from Nasdaq which could have a material adverse effect on our financial condition and could make it more difficult for stockholders to sell their shares.
  • We do not intend to pay cash dividends on our common stock in the foreseeable future.
  • If our stock price fluctuates, you could lose a significant part of your investment.
  • Techniques employed by short sellers may in the future drive down the market price of our common stock.
  • If securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding our common stock, then our stock price and trading volume could decline.
  • The market price of our stock may be highly volatile, and you could lose all or part of your investment.
  • Your ownership may be diluted if additional capital stock is issued to raise capital, to finance acquisitions or in connection with strategic transactions.
  • We may be required to issue up to 271,846 shares of common stock in connection with the reverse stock split we completed on October 24, 2024, and we may be subject to potential liability if it is determined that we are required to issue such shares and we fail to issue such shares on a timely basis.
  • The sale of our common stock by our stockholders, or the perception that stock sales may occur, could cause the price of our common stock to decline.
  • Provisions of the Series A, B and C Warrants we issued could discourage an acquisition of us by a third party.

Legal proceedings

From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time-consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. However, we are currently not a party to any pending legal actions. We have insurance policies covering any potential losses where such coverage is cost effective.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
    SEC EDGAROther events
  22. 22
  23. 23
    SEC EDGAROther events
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42